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Abstract 28 
Objectives 29 
Azithromycin treatment of Chlamydia trachomatis (CT) may not be adequate to treat concomitant 30 
Mycoplasma genitalium (MG) infection, and particularly if MG has macrolide resistance associated 31 
mutations (MG-MRAM). We estimated prevalence of co-infections of CT with MG carrying MRAM, 32 
and risk factors for MG-MRAM amongst a sexual health clinic (SHC) population. 33 
Study Design and Setting 34 
Among symptomatic and STI-contact clinic attendees in London, prevalence of CT-MG co-infection 35 
and MG-MRAM were estimated using nucleic acid amplification testing and Sanger sequencing 36 
respectively, and their associated risk factors analysed using logistic regression.  37 
Results 38 
MG prevalence was 7.5% (23/307), 17.3% (30/173) and 11.4% (8/70) in females, men-who-have-sex-39 
with-women (MSW) and men-who-have-sex-with-men (MSM); MG co-infection in CT-infected 40 
participants represented 28.0% (7/25), 13.5% (5/37), 0.0% (0/0), respectively. Presence of MG-41 
MRAM was in 39.1% (9/23) female swabs, 70.0% (21/30) MSW urine and 83.3% (5/6) MSM rectal 42 
swabs. In multivariate analyses, co-infection with another STI was strongly associated with MG-43 
MRAM (OR: 7.19; 95%CI:2.4-21.5). 44 
Conclusion 45 
A significant proportion of CT-positive participants were co-infected with MG, with high rates of MG-46 
MRAM. Our findings suggest MG and MRAM testing should be prioritised for symptomatic and STI-47 
contact females and MSW, and possibly in those with CT. Azithromycin may need to be avoided in CT 48 
positive patients for whom these tests are not available. 49 
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Introduction  
Mycoplasma genitalium (MG), increasingly recognised as an important sexually transmitted infection 50 
(STI) and cause of genitourinary discharge(1), is estimated to be responsible for 10-30% of non-51 
gonococcal urethritis (NGU) cases (2,3) and is also associated with cervicitis and pelvic inflammatory 52 
disease in women(4). It is unclear if MG causes symptomatic rectal infection, as few data are available, 53 
although associations with proctitis have been reported in MSM(5). Despite this, targeted testing for 54 
MG in United Kingdom (UK) sexual health clinics (SHCs) is not widely implemented, perhaps due to 55 
slow uptake of new commercially available CE-marked diagnostic tests.  56 
Until recently, guidelines recommended single dose therapy azithromycin 1g for treatment of NGU 57 
(5),  which is associated with high rates of MG treatment failure[1] and selection of 23S rRNA gene 58 
mutations(6). Increasingly, data from Asia and Australia detail outbreaks of resistance to a second 59 
line treatment for MG, fluoroquinolones(7),  resulting primarily from mutations in the quinolone 60 
resistance-determining region (QRDR) of the parC gene of DNA topoisomerase IV(8), leaving few 61 
treatment options available for some patients. Newer treatment guidelines suggest using 62 
doxycycline for one week to reduce bacterial load, which by itself has poor efficacy (6), followed by 63 
extended dose azithromycin to improve rates of cure(8,9).  64 
UK MG prevalence data are primarily reported at population level(10) and apart from our previous 65 
report of MG in symptomatic men-who-have-sex-with-women (MSW) from one London SHC(11), 66 
few data are available for symptomatic clinic attendees, particularly females and men-who-have-67 
sex-with-men (MSM). Studies across the USA and Europe have identified high rates of co-infection 68 
with CT and NG(15,16) but UK studies are lacking, and there is a global lack of data on prevalence of 69 
MG infection and macrolide resistance.  70 
Undiagnosed MG co-infection presents challenges to the management of other STIs. For example, a 71 
first-line treatment for CT infection is doxycycline(17) for one week, which has poor efficacy as a 72 
single agent against MG (6,15). In the treatment of Neisseria gonorrhoeae (NG), use of single dose 73 
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azithromycin 1g in dual therapy could risk selection of macrolide resistant MG (6,16). To determine 74 
clinical management implications of undiagnosed MG infection and resistance using data from a sub-75 
study of a larger programme of work (the “Precise Study: a point of care antimicrobial resistance test 76 
for Neisseria gonorrhoeae and Mycoplasma genitalium infection – ensuring accurate therapy and 77 
antibiotic stewardship in sexual health medicine”, aimed at to develop and evaluating rapid nucleic 78 
acid amplification test (NAAT)-based Point of Care tests (POCTs) for multiple STIs and AMR detection 79 
[http://www.preciseresearch.co.uk/]), we aimed to estimate prevalence, co-infections, macrolide 80 
and fluoroquinolone resistance associated mutations, and associated risk factors of MG infection in 81 
STI-contacts or symptomatic females, MSW and MSM, attending inner London SHCs.  82 
 83 
Methods  84 
Study design 85 
Data were collected as part of the larger “Precise Study”. The target recruitment numbers for the 86 
“Precise Study” were 50 NG positives, 50 MG positives, 30 Trichomonas vaginalis (TV) positives, and 87 
70 CT positives from 500 females and 500 males (100 of which to be MSM). (In order to reach these 88 
targets, symptomatic patients and sexual contacts of individuals with CT, NG, TV or NGU were 89 
targeted for recruitment. Ethical approval was provided by London Bridge Research Ethics 90 
Committee (reference 13/LO/0691).  91 
Recruitment 92 
Participants were prospectively recruited between March 2015 and March 2016. Females and MSW 93 
were recruited from one SHC, however, due to initial poor MSM recruitment in that clinic, MSM 94 
recruitment was extended to a further two SHCs in order to achieve the 100 MSM participant target 95 
for the “Precise Study”. Men who reported sex with men and women were classified as MSM. 96 
Patient eligibility was determined using triage forms, indicating whether patients met inclusion 97 
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criteria to participate in the “Precise Study”: aged ≥16 years; attending SHC for routine STI testing 98 
including CT and NG (Nucleic acid amplification test  [NAAT] testing); symptomatic (itching, genital 99 
discharge (all participants), rectal discharge (MSM only), pain/burning when urinating, dysuria, 100 
dyspareunia, post-coital bleeding, intermenstrual bleeding, rectal bleeding (MSM only) and pelvic 101 
abdominal pain) or being a sexual contact of someone with CT, NG, TV or NGU; and willing to 102 
provide appropriate samples (see Specimen Collection, below). Under the eligibility criteria, all MSM 103 
were required to be ‘willing to provide’ additional urine, rectal and pharyngeal samples, however 104 
failure to provide one of the above did not result in exclusion from the study.  105 
Patients were approached by research study staff and provided written informed consent to 106 
participate in the study prior to seeing a healthcare professional. Study staff populated case report 107 
forms capturing basic demographic, clinical and behavioural data.  108 
Specimen collection 109 
 Research samples were collected after routine sample collection. Females provided an additional 110 
vulvovaginal swab (VVS), either self- or healthcare-collected, in eNAT media (Copan, Italy). All males 111 
provided residual first catch urine and MSM provided additional pharyngeal swabs (collected by a 112 
healthcare professional) and additional rectal swabs (blind or via proctoscopy). One of each was 113 
placed in eNAT.  114 
Research sample processing 115 
DNA was extracted using Virus/Pathogen Midi kit (Qiagen, Germany) with the QIAsymphony 116 
instrument (Qiagen). Real-time PCR reactions were run using the Rotor-Gene Q 5plex HRM PCR 117 
thermocycler (Qiagen). Samples collected were processed using the FTD Urethritis plus kit (Fast 118 
Track Diagnostics, Luxembourg) for the detection of MG, and final resolved sample status 119 
determined using a discrepant analysis approach. See Supplementary Material for detailed testing 120 
methodology.  121 
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Resistance detection 122 
Sanger sequencing was used to determine presence or absence of mutations associated with 123 
resistance to azithromycin and fluoroquinolones in MG. The positioning of resistance-associated 124 
mutations and primers used for PCR and sequencing can be found in the Supplementary Material 125 
along with detailed testing methodology. 126 
Analysis 127 
Analyses included descriptive analysis of participant characteristics. Sample size was determined by 128 
the larger “Precise Study”.  129 
Data analysis  130 
Data were analysed using Stata (StataCorp, Texas, USA) for Windows v15.1. Data validation and 131 
cleaning was undertaken at both St George’s, University of London and Public Health England 132 
independently. Missing data were checked with corresponding clinics and any participants missing 133 
one or more sets of results (either clinical NAAT or research results) were excluded from analysis.  134 
Prevalence and 95% confidence intervals (CIs) for MG, CT and NG were derived by gender and 135 
anatomical site. Comparison of differences in demographic characteristics and other risk factors for 136 
MG macrolide resistance associated mutations (MG-MRAM). (MRAMs) and co-infection was derived 137 
using Pearson's chi-squared test. A p-value <0.05 was considered statistically significant.  138 
Odds ratios and 95%CIs of demographic characteristics and other risk factors associated with MG 139 
MRAMs were derived from univariate logistic regression. Factors with a p <0.10 were further 140 
evaluated for independent effect using multivariate analysis, using a forward stepwise approach. 141 
The reference group for each category was that with the highest number of participants. 142 
Results  143 
Participant overview 144 
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Of the 786 patients approached, 308 females, 173 MSW and 88 MSM provided clinic and research 145 
test results. Of the 88 MSM who consented to have samples taken from all three anatomical sites, 146 
70 participants provided samples from all three sites, and a total of 79 urine, 79 rectal and 85 147 
pharyngeal samples were received. Reasons samples were not collected from MSM included: 148 
accidental disposal at clinic, inadvertent neglect of sample taking by participant, or failure of 149 
collection by clinician during examination.  One female participant also had an unresolved discrepant 150 
result and was removed from analysis, resulting in a total of 550 participants (307 females, 173 MSW 151 
and 70 MSM) providing a full set of samples along with routine NAAT and research test results. The 152 
proportion of females, MSW and MSM who were symptomatic was: 98.7% (304/308), 97.1% 153 
(168/173), and 62.9% (44/70), respectively. The corresponding proportions who were sexual 154 
contacts of an individual with CT, NG, TV or NGU were 6.8% (21/308), 12.7% (22/173), and 41.4% 155 
(29/70).  156 
CT, MG and NG infection and co-infection prevalence by population group 157 
Of the total 723 samples, discrepant analysis was needed for 4 CT diagnoses, 20 NG diagnoses, and 5 158 
MG diagnoses. Prevalence of any infection (CT, MG, NG) was 13.6% (42/307) in females, 39.3% 159 
(68/173) in MSW, and 45.7% (32/70) in MSM (all sample types combined). Among those positive for 160 
any of these infections, co-infection (≥1 CT, MG or NG within a sample) was present in 19.0% (8/42), 161 
13.2% (9/68) and 15.6% (5/32), respectively. There was no difference between rates of co-infections 162 
in males and females (p=0.124). 163 
In MSM, prevalence of any infection by anatomical site was 21.5% (17/79), 40.5% (32/79) and 18.8% 164 
(16/85) in urine, rectal and pharyngeal samples, respectively. Among positives, co-infection was 165 
present in 5.9% (1/17), 6.3% (2/32) and 0.0% (0/16), respectively.  166 
Prevalence estimates of individual infections and co-infections are shown in Table 1. Prevalence of 167 
CT and MG was highest in MSW, whereas NG was most prevalent in MSM. Co-infection was present 168 
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in all population groups, although differences existed by pathogen.  There were no MG-NG co-169 
infections detected in any participants.  170 
 171 
Table 1: Resolved CT, NG and MG prevalence and co-infection in females, MSW and MSM 172 
Total 
participants 
Females 
307 
MSW 
173 
MSM 
70 
 No. 
positive 
(%) 
95%CI 
 
No. 
positive 
(%) 
95%CI 
 
No. 
positive 
(%) 
95%CI 
 
Overall CT 
infections 
25 (8.1) 5.6-11.7 37 (21.4) 16.0-28.1 9 (12.9) 6.9-22.7 
Overall MG 
infections 
23 (7.5) 5.0-11.0 30 (17.3) 12.4-23.7 8 (11.4) 5.0-11.0 
Overall NG 
infections 
4 (1.3) 0.5-3.3 10 (5.8) 3.2-10.3 27 (38.6) 28.1-50.3 
CT Mono 
infections 
17 (5.5) 3.5-8.7 28 (16.2) 11.4-22.4 4 (5.7) 2.2-13.8 
MG Mono 
infections 
16 (5.2) 3.2-8.3 25 (14.5) 10.0-20.5 8 (11.4) 5.0-11.0 
NG Mono 
infections 
1 (0.3) 0.0-0.2 6 (3.5) 1.6-7.4 22 (31.4) 21.8-43.0 
CT-MG co-
infection 
5 (1.6) 0.7-3.8 5 (2.9) 1.2-6.6 0 (0) - 
CT-NG co-
infection 
1 (0.3) 0.0-0.2 4 (2.3) 0.9-5.8 5 (7.1) 3.1-15.7 
CT-MG-NG 
co-infections 
2 (0.7) 0.2-2.3 0 (0) - 0 (0) - 
MG-NG co-
infection 
0 (0) - 0 (0) - 0 (0) - 
 173 
CT, MG and NG infection and co-infection prevalence by anatomical site in MSM 174 
As shown in table 2, in MSM that provided any sample, there were no MG co-infections at any 175 
anatomical site. CT-NG co-infections were identified in urine and rectal samples, but there were no 176 
pharyngeal co-infections.   177 
 
 
9 
 
 178 
Table 2: CT, NG and MG prevalence and co-infection by anatomical site in MSM 179 
Total 
samples 
URINE 
79 
RECTAL 
79 
PHARYNGEAL 
85 
 No. 
positive 
(%) 
95%CI No. 
positive 
(%) 
95%CI No. 
positive 
(%) 
95%CI 
Any 
infection of 
CT/NG/MG 
 17 (21.5) 13.9-31.8 32 (40.5) 30.4-51.2 16 (18.8) 11.9-28.4 
Overall CT 
infections 
5 (6.3) 2.7-14.0 6 (7.6) 3.5-15.6 1 (1.2) 0.2-6.4 
Overall NG 
infections 
11 (13.9) 8.0-23.2 22 (27.8) 19.2-38.6 15 (17.6) 11.0-27.1 
Overall MG 
infections 
2 (2.5) 0.7-8.8 6 (7.6) 3.5-15.6 0 (0) - 
CT-MG co-
infection 
0 (0) - 0 (0) - 0 (0) - 
CT-NG co-
infection 
1 (1.3) 0.2-6.8 2 (2.5) 0.7-8.8 0 (0) - 
CT-NG-MG 
co-infections 
0 (0) - 0 (0) - 0 (0) - 
MG-NG co-
infection 
0 (0) - 0 (0) - 0 (0) - 
 180 
MG macrolide and fluoroquinolone resistance by population group 181 
Among females and MSM, there were no mutations in either gyrA or parC associated with 182 
fluoroquinolone resistance for MG. In MSW, one MG (mono-infection) (3.3%, 1/30 95%CI 0.6-16.7) 183 
had mutations in parC at position S83. No resistance towards macrolides or fluoroquinolones was 184 
detected in MG-positive MSM urogenital or pharyngeal samples. As shown in table 3, MRAM was 185 
detected in female swabs, MSW urine and MSM rectal samples, for both mono- and co-infections.  186 
 187 
Table 3: Macrolide resistant samples as determined by the presence of A2058 and A2059 mutations  188 
in 23S rRNA 189 
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*There were no MG-positive pharyngeal samples 190 
R+: macrolide resistant; n=number of MG positives; MG: Mycoplasma genitalium; CT: Chlamydia 191 
trachomatis; MSW: Men-who-have-sex-with-women; MSM: men-who-have-sex-with-men 192 
 193 
Risk factors associated with MG macrolide resistance 194 
Risk factors included in the logistic regression model for association with MG MRAMs are shown in 195 
Table 4.  In univariate analysis, risk factors with strong evidence of association with MG MRAMs 196 
were sexual orientation, age, ethnicity, recent STI diagnosis and co-infection with another STI.  197 
In multivariable analysis, compared to MSW, females were less likely to have MG MRAMs (AOR (95% 198 
CI): 0.23 (0.09- 0.58)). Being of Black ethnicity (2.64 (1.06-6.56)) increased the odds of having 199 
MRAMs in MG samples compared to those of White ethnicity.  Co-infection with another STI was 200 
associated with MG MRAMs (7.19 (2.41-21.46)). 201 
 202 
 
 
Females MSW MSM Rectal 
samples* 
MSM Urine samples* 
R+/n % 
(95%CI) 
R+/n % 
(95%CI) 
R+/n % 
(95%CI) 
R+/n % 
(95%CI) 
Overall 
MG 
infections 
9/23 39.1 
(22.2-
59.2) 
21/30 70.0 
(52.1-
83.3) 
5/6 83.3 
(43.7-
97.0) 
0/2 0 
(0-84.2) 
MG mono 
infection 
6/16 37.5 
(18.4-
61.4) 
17/25 68.0 
(48.4-
82.8) 
5/6 83.3 
(43.7-
97.0) 
0/2 0 
(0-84.2) 
CT-MG co-
infection 
3/5 60.0 
(23.1-
88.2) 
4/5 80.0 
(37.6-
96.4) 
- - - - 
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Table 4: Univariate and multivariable logistic regression analysis of factors associated with MG 203 
macrolide resistance (MRAM) 204 
  Univariate Multivariable 
 Prevalence 
of MG 
MRAMs 
 
Odds ratio (95% 
confidence 
interval) 
P value Adjusted odds 
ratio (AOR) (95% 
confidence 
interval) 
P value 
Sexual 
orientation 
MSW 
MSM 
Females 
 
 
12.1 
4.3 
2.9 
 
 
1 
0.32 (0.09-1.12) 
0.22 (0.10-0.49) 
 
 
- 
0.076 
<0.001 
 
 
1 
0.25(0.05-1.37) 
0.23 (0.09-0.58) 
 
 
- 
0.309 
<0.05 
Age group 
(years) 
16-19 
20-24 
25-34 
35+ 
 
 
13.0 
6.5 
5.1 
4.8 
 
 
1 
0.46 (0.15-1.42) 
0.35 (0.14-1.03) 
  0.34 (0.10-1.01) 
 
 
- 
0.178 
<0.05 
0.072 
 
 
1 
0.41 (0.11-1.48) 
0.30 (0.09-1.07) 
0.34 (0.08-1.38) 
 
 
- 
0.174 
0.063 
0.131 
Ethnicity 
White 
Asian 
Black 
Other 
 
2.8 
10.0 
11.5 
7.1 
 
1 
 3.83 (0.77-19.03) 
4.49 (1.97-10.25) 
2.65 (0.79-8.92) 
 
- 
0.101 
<0.001 
0.116 
 
1 
3.16 (0.52-19.30) 
2.64 (1.06-6.56) 
2.18 (0.53-8.91) 
 
- 
0.213 
<0.05 
0.278 
Co-infection* 
No 
Yes 
 
4.7 
32.0 
 
1 
9.03 (3.39-24.05) 
 
- 
<0.001 
 
1 
7.19 (2.41-21.46) 
 
- 
<0.001 
Recent STI 
No 
Yes 
 
4.9 
9.6 
 
1 
2.03 (0.91-4.57) 
 
- 
0.080 
 
1 
1.62 (0.64-4.11) 
 
- 
0.305 
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Sexual 
contact of 
individual 
with an STI 
No 
Yes 
 
 
 
6.3 
4.2 
 
 
 
1 
0.64 (0.19-2.17) 
 
 
 
- 
0.479 
 
 
 
- 
- 
 
 
 
- 
- 
Sex Abroad 
(within the 
past 3 
months) 
No 
Yes 
 
 
 
5.5 
4.9 
 
 
 
1 
0.89 (0.20-3.91) 
 
 
 
- 
0.873 
 
 
 
- 
- 
 
 
 
- 
- 
Sex with 
someone 
from outside 
the UK 
(within the 
past 3 
months) 
 No 
Yes 
 
 
 
 
 
6.3 
3.4 
 
 
 
 
 
1 
0.53 (0.18-1.58) 
 
 
 
 
 
- 
0.252 
 
 
 
 
 
- 
- 
 
 
 
 
 
- 
- 
Regular 
partner 
No 
Yes 
 
 
3.4 
5.9 
 
 
1 
1.76 (0.51-6.08) 
 
 
- 
0.368 
 
 
- 
- 
 
 
- 
- 
MRAM: MG macrolide resistance; MSW: Men who have sex with women; MSM: men who have sex 205 
with men; STI: sexually transmitted infection; AOR: adjusted odds ratio 206 
*Co-infection: ≥1 CT, MG or NG within a sample 207 
Discussion  208 
This study confirms that in an inner London sexual health clinical setting among STI-contacts and 209 
symptomatic patients, MG prevalence is high overall, and in our sample set particularly those 210 
diagnosed with CT infection. MG-MRAM infections were present in nearly 40% of MG-positive 211 
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samples from women, two-thirds of MSW MG-positive samples, and were more likely to be found in 212 
those with a co-infection than in those with a mono-infection.  213 
These findings have implications for clinical management of STI-contacts and symptomatic patients 214 
in SHCs. Although the UK first line treatment for CT, doxycycline, is a poorly effective monotherapy 215 
for MG infection(16,17), recent evidence suggests pre-treatment with doxycycline can significantly 216 
reduce bacterial load (p<0.001) (8).  Additionally, increasing evidence suggests 1g azithromycin, the 217 
UK’s second line CT therapy, may not be as effective for CT treatment as previously thought(18,19) 218 
and is associated with a high rate of MG treatment failure, commonly due to selection or presence 219 
of 23S rRNA mutations (17,20). Importantly, high rates of MRAMs in our study data and macrolide 220 
resistance worldwide (30-80%)(12,21,22) suggest azithromycin monotherapy should not be used, at 221 
any dose, without appropriate resistance testing.  222 
Our study also highlights the potential need for MG testing in those clinically indicated, as already 223 
recommended in a number of treatment guidelines (9,23,24). Despite MG testing being adopted in 224 
some UK SHCs, it is still far from universally implemented. Implications of our findings on clinical 225 
management would very much depend on availability of both MG and macrolide resistance tests. 226 
Such tests are now commercially available (25). In situations where it is not feasible to use such tests 227 
on all indicated patients, our findings suggest testing could be directed at symptomatic and STI-228 
contact patients with CT infection; others have demonstrated utility targeting testing at those 229 
diagnosed with NGU (9,24). Thus, in all scenarios where symptoms may suggest a CT or MG infection 230 
(with or without access to a routine MG test), treating with doxycycline at baseline followed by 231 
either test of cure (TOC) or further treatment directed at MG infection may be sensible approaches 232 
to management, and reduce potential macrolide resistance selection pressure (6,26). However, 233 
based on our dataset, testing only CT positives who are STI-contacts or symptomatic would still miss 234 
high numbers of MG infections (72% in our study), and would not be adequate. Cost-effectiveness of 235 
deploying macrolide resistance tests would depend in-part on there being sufficient numbers of 236 
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susceptible strains circulating and effective alternative treatment options available. Given the high 237 
rate of macrolide resistance, and emerging fluoroquinolone resistance worldwide (6,22,27,28), 238 
investigating the public health impact and cost-effectiveness of these tests is important.   239 
Our study included results from three population groups (females, MSW and MSM). Recruitment 240 
was restricted to those with symptoms or who were sexual contacts of an individual with CT, NG, TV, 241 
or NGU, to inform management of this patient group, in-line with evidence that MG testing should 242 
not be expanded to asymptomatic individuals(29). For MSM, participants were sampled from three 243 
anatomical sites and from three London locations, providing a better overall representation of 244 
individual infection status. Finally, testing was performed in a robust manner with all three clinics 245 
using the same CT/NG routine NAAT.  246 
There are some limitations to this study. Firstly, these data were collected as part of a larger study 247 
(the “Precise Study”), the aim of which was the development and evaluation of a NAAT-based POCT 248 
for NG and MG infection and resistance. Consequently, symptomatic patients and sexual contacts of 249 
individuals with CT, NG, TV or NGU were targeted for recruitment in order to increase the likelihood 250 
of STI-positive individuals. This however means we are unable to comment on the prevalence of MG 251 
infection or resistance in asymptomatic patients, and the consequent importance of testing (and 252 
treating) these individuals for MG.  253 
Secondly, participants were recruited on the basis of self-reported symptoms, which may vary 254 
between females and males. For example, physiological vaginal discharge is not uncommonly 255 
reported as a symptom in females, and pathological discharge often includes non-STIs such as 256 
candidiasis and bacterial vaginosis. Another limitation is that, common to many studies with 257 
heterosexual women, extra-genital testing was not offered despite recent evidence detailing high 258 
rates of rectal CT infection in this population group (19,30,31) . Therefore, it is possible prevalence 259 
and co-infections in female participants may have been underestimated. Additionally, the absence of 260 
NG-MG co-infections warrants further investigation as this could be related to the relatively small 261 
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sample size of the MSM participants. Samples were only collected from patients attending London 262 
clinics and data collected from MSW and females from one clinic, so may not be representative of 263 
the wider symptomatic population. Finally, although low numbers, TV results were excluded from 264 
this analysis due to testing only with the laboratory test without confirmatory testing, and for the 265 
original purpose of this evaluation within the “Precise Study”, CT, MG and NG were tested using a 266 
discrepant analysis approach. 267 
Our risk factor analysis demonstrated that men, co-infection with another STI and black ethnicity 268 
were all independent risk factors associated with macrolide resistant MG. Having a co-infection was 269 
the strongest independent risk factor, perhaps indicating these participants were at a higher risk of 270 
previous STIs or, as MG is not routinely tested for, could be due to historic missed infection. 271 
Alternatively, these data may be a surrogate for previous azithromycin exposure and may represent 272 
and emphasise a need for vigilance in clinical history taking, particularly for subjective factors such as 273 
patient recall of previous antibiotic use or an STI diagnosis. We did not have data on previous 274 
exposure to azithromycin or prevalence of recent diagnoses of non-specific genital infection. History 275 
of azithromycin therapy around the time of the study may have helped explain these findings. This 276 
further emphasises the need for MG testing, suggesting that in the presence of CT or NG infection, 277 
use of azithromycin to treat any MG co-infection should be avoided unless specifically testing for MG 278 
resistance.  279 
We found a low prevalence of genotypic fluoroquinolone resistance in our sample set (0.18%) 280 
compared to other prevalence studies reporting  8.6-53.1% (22,32) supporting the development of 281 
new diagnostic fluoroquinolone resistance tests to help with resistance-guided therapy.  282 
In summary, our data show high prevalence of co-infection of MG with CT, and high prevalence of 283 
macrolide resistant MG, particularly in CT co-infections, amongst symptomatic patients and contacts 284 
of STIs. The findings suggest the need for MG testing, in particular for the management of STI-285 
contact and symptomatic females and MSW, and possibly in those with CT. Our MSM dataset had 286 
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few MG positives with MRAMs, which combined with the current lack of evidence for the role of MG 287 
in MSM sexual health, means recommendations for this population cannot be made. For 288 
management of CT infections, data support an approach of doxycycline as first-line therapy to avoid 289 
azithromycin for patients whose MG status and resistance profile are unknown. In those 290 
subsequently testing positive for MG, azithromycin should only be used following the demonstration 291 
that the infection strain is genotypically sensitive.  292 
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